Topics:
Gastrointestinal Cancers • Medical Oncology
How would you approach adjuvant therapy for low-risk stage III colon cancer (T2N1) in an elderly patient with a good PS?
How would being MSI-H/dMMR influence your choice of adjuvant treatment?
Answer from: Medical Oncologist at Academic Institution
Patients with stage III colon cancer should receive adjuvant therapy to reduce recurrence risk. FOLFOX adjuvant treatment should reduce relative recurrence risk by about 1/3 (e.g from 35% to 25%). Based on the IDEA collaboration, 3 months of treatment is approximately equal to 6 months of adjuvant ...
Sign in or Register to read more